The purpose of this study is to determine if a fat emulsion comprised of omega-3 fatty acids,
Omegaven, would be beneficial in the management of steatotic liver injury in parenteral
nutrition (PN) by its inhibition of de novo lipogenesis, the reduction of arachidonic
acid-derived inflammatory mediators, prevention of essential fatty acid deficiency through
the presence of small amounts of arachidonic acid, and improved clearance of lipids from the
serum.